Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-Term Safety and Efficacy of Moxifloxacin in Bronchiectasis Patients
Sponsor: Assiut University
Summary
Bronchiectasis is a chronic respiratory disease characterized by recurrent infections, inflammation, and progressive lung damage. Frequent exacerbations are associated with increased morbidity, accelerated lung function decline, and reduced quality of life. Preventing exacerbations is a key therapeutic goal. Moxifloxacin, a fluoroquinolone antibiotic with broad-spectrum activity, may play a role in intermittent eradication therapy to reduce bacterial load, achieve microbiological clearance, and minimize exacerbation frequency. This randomized controlled trial will evaluate the effectiveness and safety of long-term intermittent moxifloxacin therapy compared with standard care in patients with non-cystic fibrosis bronchiectasis.
Official title: Effectiveness and Safety of Long-Term Intermittent Moxifloxacin Eradication Therapy in Non-Cystic Fibrosis Bronchiectasis: A 12-Month Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
140
Start Date
2025-12-01
Completion Date
2027-01-01
Last Updated
2025-12-10
Healthy Volunteers
No
Conditions
Interventions
Intermittent Moxifloxacin + Standard Care
Moxifloxacin 400 mg orally once daily for 7 days every 8 weeks (total 6 cycles over 12 months), in addition to guideline-based standard care
Standard Care (in control arm)
Participants will receive guideline-based management of bronchiectasis without long-term suppressive antibiotics.
Locations (1)
Assiut University hospital
Asyut, Asyut Governorate, Egypt